While hematopoietic growth factors are beneficial in many clinical settings, they can also have potential toxic side effects. Overstimulation of blood cell production can lead to conditions such as thrombocytosis or leukocytosis, which can increase the risk of thromboembolic events. Additionally, the use of these growth factors in patients with certain types of cancer may stimulate the growth of malignant cells, making careful consideration essential before their use.
